Jan Buch Andersen

CEO and Founder, PhD

Jan is a serial entrepreneur and native Dane who has been involved with numerous start-ups in the field of biotechnology. He received his Ph.D. from the University of Copenhagen in plant molecular biology in 1989. After leaving academia, he built a distribution company that specialized in molecular biology/cell culture reagents in Denmark, which was sold to Fisher Scientific in 2002. He has had Sales Manager tenures with both Invitrogen and Roche Diagnostics, leading to the co-founding of InMold Biosystems, a company in the advanced laboratory plastics area allowing functional proteins to be moulded into plastic surfaces. After his withdrawl he spent a year in India working for Bangalore Genei, leaving after it was sold to Merck Millipore for a position as Managing Director of ArcticZymes in Tromsø, Northern Norway. Still based in Tromsø, Jan founded Barentzymes in 2014, and the Njorth Bio_group in 2015/16.

Over the years Jan has acquired a solid commercial network and deep understanding of what it takes to do business on a global scale. He is commercial in all he does, and knows every aspect of building a bio-based business from the ground up. Jan has experience in a wide variety of publicly traded, international companies with offices located throughout the world. He has delivered outstanding results leading turn-around processes at several troubled companies.

Jan has been the chairman for the Industrial Biotech Network Norway, which has added substantially to his international network in the field of bioeconomic development. He is also a member of the program board for the largest biotechnology program (Biotek2021) at the Norwegian Research Council and has been an invited speaker to many international conferences on industrial biotechnology.

Read more

Erik Kromann

Chairman of the Board

Erik Kromann holds a B.Sc. in chemical engineering from the Danish Technical University and a business degree in accounting (HD) from the Copenhagen Business School.
He worked at Sadolin & Holmblad (now Akzo Nobel) for 12 years holding various positions in Denmark and abroad. Having been Executive Vice-President, Sales, and Regional Director, the Americas for Hempel Coatings, Inc., he participated in a management buy-in of the pharmaceutical company Scanpharm A/S as Executive Vice-President, Science and Technology. For 7 years he worked for the Superfos Group as President for Superfos Chemicals and later Superfos Biosector (now Brenntag Biosector), a biotech company focused on vaccine adjuvants.

In recent years he has hold responsibilities as President and CEO in start-ups in the biotech field, and Director in a number of high-tech companies. From September 2000 until July 2007 he has been a licensing professional assisting companies and research institutions in technology transfer and commercialization. His responsibilities also encompassed NOVI Innovation A/S (now Borean Innovation A/S), a science incubator that provides financing and incubator facilities to innovative start-up companies.

Post retirement in July 2007 he has been active as director in start-up bio- and med-tech companies.

Read more